News

The cancer therapeutic based on patient’s own modified adult mesenchymal stem cells is running under the portfolio name Agenmestencel-T. In December 2012 apceth has concluded the first round

The study will conducted in healthy volunteers who received oral Factor Xa inhibitor Xarelto (rivaroxaban). Phase 2 study designed to assess the safety of varying doses of PRT4445

The company has voluntarily issued the recall to consumers, retail customers and wholesalers due to bottle closure defect. The recalled products were produced at a Novartis Consumer Health

GSK is expecting to assess the safety and efficacy profile of varying doses of GSK2586184 in a multi-center placebo-controlled Phase 2 study scheduled for 12 weeks, in SLE

StemEx, which is a graft of an expanded population of stem/progenitor cells derived from part of a single unit of umbilical cord blood, is transplanted by IV administration

Glenmark Biologics Research Centre in La Chaux-de-Fonds, Switzerland, discovered GBR 830. GBR 830 is a potent therapeutic option for patients suffering from immune pathologies including autoimmune diseases like

The certification covers Bend’s manufacture of clinical pharmaceutical supplies for human consumption and testing of the supplies at the company’s GMP facilities. Bend Research CEO Rod Ray said,

The partnership will leverage RaQualia’s core expertise in drug discovery and development, and Interprotein’s platform technology, INTerprotein’s Engine for New Drug Design (INTENDD). Under the agreement, RaQualia will

Under the agreement, Pharmasyntez has gained rights to market and distribute Oasmia’s Paclical in Russia and the countries encompassed by the Commonwealth of Independent States (CIS). The agreement,